ArticleThe Lancet regional health. Southeast Asia2026
Burden of MASLD and liver fibrosis: evidence from Phenome India cohort.
Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice.Journal of internal medicine · 2026Review
- Determinants of Metabolic Dysfunction-Associated Steatotic Liver Diseases in Patients with Type 2 Diabetes Mellitus.Journal of clinical medicine · 2026Article
- Scale of unmet solid organ transplantation need in India: a projection for organ transplant need by 2040.The Lancet regional health. Southeast Asia · 2026Article
- Association of SPISE with prevalent and incident MASLD: a two-stage population-based study and development of a risk prediction model.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic-dysfunction-associated steatotic liver disease (MASLD) is rising globally, including in India, yet community-based data remain scarce. We address this critical knowledge gap by assessing the prevalence, distribution, and characteristics of MASLD subgroups and fibrosis, leveraging the Phenome India cohort. Methods: In this prospective study, we recruited 10,267 adults across 37 laboratories of the Council of Scientific and Industrial Research (CSIR) from 27 Indian cities. All permanent staff members of the CSIR, including current employees, retirees, and their spouses who responded to the recruitment campaign and provided voluntary consent, were considered for participation in the Phenome India Cohort. Steatosis and fibrosis were assessed using Transient Elastography, along with associated clinical, biochemical, cytokine and anthropometric data. Overall, crude and age-adjusted prevalence rates were estimated in the study population and various subgroups. Findings: Of 10,267 individuals screened, 7764 were included, 3712 (47.8%) fulfilled MASLD criteria, corresponding to an age-adjusted prevalence of 38.9% (95% CI 37.2-40.6). Significant fibrosis, defined as liver stiffness measurement (LSM) ≥8.2 kPa (≥F2), was more frequent in MASLD (6.3% [234 of 3688]) than in cases without-MASLD (1.7% [69 of 4027]), corresponding to an age-adjusted prevalence of 4.1% in MASLD. Overall age-adjusted prevalence of significant fibrosis was 2.4%, which clustered in older adults (>60 years) and in those with diabetes or obesity class II, with evidence of possible regional variation. Interpretation: MASLD affected over one-third of participants. Site-specific disparities were observed, which suggest the need for large-scale longitudinal studies to elucidate region-specific risk factors and temporal trends. Community-based awareness and targeted public health interventions across diverse geographical and socio-cultural settings in India may help curb the rising burden. Funding: The work was funded by CSIR, India grant HCP47.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.